NCT03297359View on ClinicalTrials.gov

WAVe Study - Weight Adjusted Dalteparin for Patients Over 90 kg With Acute Cancer Associated Venous Thromboembolism

PHASE2TerminatedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

March 21, 2018

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2023

Conditions
CancerVenous ThromboembolismObesity
Interventions
BIOLOGICAL

Dalteparin

daily subcutaneous injection of weight-adjusted dalteparin

Trial Locations (5)

T6G 2V2

Alberta Health Services, Edmonton

B3H 1V7

Nova Scotia Health Authority, Halifax

Unknown

Juravinski Hospital, Hamilton

K1H 8L6

The Ottawa Hospital, Ottawa

M5G 1J6

Toronto General Hopsital, Toronto

Sponsors
All Listed Sponsors
collaborator

Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network

NETWORK

lead

Ottawa Hospital Research Institute

OTHER